Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Icotinib in EGFR-mutated NSCLC
NCT01843647Phase 2Unknown
- Sponsor
- Betta Pharmaceuticals
- Start
- Apr 2013
- Primary completion
- Dec 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of icotinib in non-small cell lung cancer (NSCLC), sponsored by Betta Pharmaceuticals. Status: unknown.
02
Drugs
icotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01843647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01843647.